Gene Therapy Delivering VIP to Joints Treats Collagen-Induced Arthritis in Mice
Lentiviral gene therapy delivering VIP complementary DNA to arthritic joints reduced inflammation and joint destruction in a mouse collagen-induced arthritis model — proof-of-concept for neuropeptide gene therapy in autoimmune disease.
Quick Facts
What This Study Found
Lentiviral VIP gene delivery to arthritic joints reduced inflammation, cartilage destruction, and bone erosion in collagen-induced arthritis mice — demonstrating neuropeptide gene therapy as a viable approach for local treatment of autoimmune joint disease.
Key Numbers
How They Did This
animal-study study.
Why This Research Matters
Relevant for neuropeptides, inflammation, immune-function.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Lentiviral VIP gene delivery to arthritic joints reduced inflammation, cartilage destruction, and bone erosion in collagen-induced arthritis mice — de
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2008.
- Original Title:
- In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.
- Published In:
- Arthritis and rheumatism, 58(4), 1026-37 (2008)
- Authors:
- Delgado, Mario(10), Toscano, Miguel G(3), Benabdellah, Karim(2), Cobo, Marien, O'Valle, Francisco, Gonzalez-Rey, Elena, Martín, Francisco
- Database ID:
- RPEP-01332
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
Gene Therapy Delivering VIP to Joints Treats Collagen-Induced Arthritis in Mice
What was found?
Lentiviral gene therapy delivering VIP complementary DNA to arthritic joints reduced inflammation and joint destruction in a mouse collagen-induced arthritis model — proof-of-concept for neuropeptide gene therapy in autoimmune disease.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01332APA
Delgado, Mario; Toscano, Miguel G; Benabdellah, Karim; Cobo, Marien; O'Valle, Francisco; Gonzalez-Rey, Elena; Martín, Francisco. (2008). In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.. Arthritis and rheumatism, 58(4), 1026-37. https://doi.org/10.1002/art.23283
MLA
Delgado, Mario, et al. "In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.." Arthritis and rheumatism, 2008. https://doi.org/10.1002/art.23283
RethinkPeptides
RethinkPeptides Research Database. "In vivo delivery of lentiviral vectors expressing vasoactive..." RPEP-01332. Retrieved from https://rethinkpeptides.com/research/delgado-2008-in-vivo-delivery-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.